FIELD: medicine.
SUBSTANCE: group of inventions relates to prediction of the risk of development of an undesired reaction related to administration of an antibody to ALK2, prediction of a response to treatment or prevention by administration of an antibody to ALK2, to a method for selection of a subject undergoing treatment or prevention by administration of an antibody to ALK2, and a method for treatment or prevention of ectopic ossification or brain tumor caused by BMP signal transmission mediated with ALK2 containing active mutation by administration of an antibody to ALK2. Methods include detection of the presence or absence of active mutation in ALK2 and mutation of an amino acid residue in position 330 of ALK in the patient. Then, it is determined that, when the patient has active mutation in ALK2 and does not have mutation of the amino acid residue in position 330 of ALK2, he/she is capable of responding to treatment or prevention by administration of the antibody to ALK2 or its antigen-binding fragment.
EFFECT: inventions allow for effective treatment or prevention of ectopic ossification or brain tumor by administration of an antibody to ALK2.
12 cl, 8 dwg, 8 ex
Title | Year | Author | Number |
---|---|---|---|
CRYSTAL STRUCTURE OF GREMLIN-1 AND INHIBITORY ANTIBODY | 2017 |
|
RU2769285C2 |
ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
ANTIBODY AGAINST LAG-3 | 2017 |
|
RU2744866C2 |
MONOVALENT ANTIBODIES TO PROPERDIN AND FRAGMENTS OF ANTIBODIES | 2018 |
|
RU2790103C2 |
ANTI-IL-5 ANTIBODIES | 2017 |
|
RU2758008C2 |
CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
EphA4 ANTIBODY | 2016 |
|
RU2719158C2 |
PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
Authors
Dates
2022-11-17—Published
2019-03-04—Filed